RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Leap Therapeutics P/S 2024

Leap Therapeutics P/S

0

Leap Therapeutics Dividend yield

Ticker

LPTX

ISIN

US52187K1016

WKN

A2DK5X

As of Apr 27, 2024, Leap Therapeutics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Leap Therapeutics P/S history

Leap Therapeutics Aktienanalyse

What does Leap Therapeutics do?

Leap Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. The company was founded in 2011 as HealthCare Pharmaceuticals Inc. and specializes in the development of new cancer therapies. The company's history began with the discovery of LIM kinase (LIMK) as a new target molecule for cancer therapies. This protein plays a role in the regulation of the cytoskeleton, which is important for cell shape and movement. Inhibiting LIMK could therefore inhibit the growth and spread of cancer cells. Leap Therapeutics has subsequently focused on the development of antibody therapies targeted against various types of cancer. The company employs a combination therapy approach, consisting of multiple drugs tailored to the specific characteristics of the tumor. The goal is to increase treatment efficacy while reducing potential side effects. Leap Therapeutics currently has several clinical trials underway, focusing on different types of cancer such as breast, lung, and colorectal cancer. A key focus is on developing therapies for patients with advanced or metastatic cancer for whom conventional treatment methods are no longer sufficient. One example of a Leap Therapeutics product is the antibody DKN-01, which targets the growth factors DKK1 and DKK2. These factors play a role in the regulation of tumor growth and metastasis and are elevated in many types of cancer. Clinical studies have shown that DKN-01 in combination with the chemotherapy drug paclitaxel has a higher response rate in patients with lung cancer compared to chemotherapy alone. Another Leap Therapeutics product is the antibody TRX518, which specifically targets the immune receptor OX40. OX40 plays a role in the activation of T lymphocytes, which are important in combating cancer cells. Clinical studies have shown that TRX518 can enhance response to cancer therapy and improve survival in patients with advanced melanoma. Leap Therapeutics' business model is based on the development and commercialization of novel therapeutics. The company collaborates closely with other biotech companies, as well as academic institutions and clinical centers, to accelerate the development of new therapies and bring them to market as quickly as possible. Overall, Leap Therapeutics is a promising biotechnology company specializing in the development of new cancer therapies. Through the targeted combination of drugs and the focus on specific target molecules, the aim is to develop highly effective therapies that offer advanced cancer patients better chances of survival and a higher quality of life. Leap Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Leap Therapeutics's P/S Ratio

Leap Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Leap Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Leap Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Leap Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Leap Therapeutics Stock

What is the price-to-earnings ratio of Leap Therapeutics?

The price-earnings ratio of Leap Therapeutics is currently 0.

How has the price-earnings ratio of Leap Therapeutics changed compared to last year?

The price-to-earnings ratio of Leap Therapeutics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Leap Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Leap Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Leap Therapeutics affect the company?

An increase in the price-earnings ratio of Leap Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Leap Therapeutics affect the company?

A decrease in the price-earnings ratio of Leap Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Leap Therapeutics?

Some factors that influence the price-earnings ratio of Leap Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Leap Therapeutics pay?

Over the past 12 months, Leap Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Leap Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Leap Therapeutics?

The current dividend yield of Leap Therapeutics is .

When does Leap Therapeutics pay dividends?

Leap Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Leap Therapeutics?

Leap Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Leap Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Leap Therapeutics located?

Leap Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Leap Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Leap Therapeutics from 4/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2024.

When did Leap Therapeutics pay the last dividend?

The last dividend was paid out on 4/27/2024.

What was the dividend of Leap Therapeutics in the year 2023?

In the year 2023, Leap Therapeutics distributed 0 USD as dividends.

In which currency does Leap Therapeutics pay out the dividend?

The dividends of Leap Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Leap Therapeutics

Our stock analysis for Leap Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Leap Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.